drugset
drugset / Trial / NCT04208620

Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus

NCT04208620 ↗

Phase 1 Completed 16 enrolled AstraZeneca MedImmune LLC · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1 study designed to assess the safety and tolerability of MEDI0382 (Cotadutide) in Japanese T2DM patients.

Timeline

Start
2020-01-21
Primary completion
2020-07-08
Completion
2020-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cotadutide Peptide — Subcutaneous

Indications

type 2 diabetes mellitus